To determine whether cerdulatinib inhibits BCR and JAK-STAT signaling pathways, we first measured the phosphorylation of SYK, PLCγ2, AKT and ERK in BCR-stimulated DLBCL cells treated with or without cerdulatinib (Figure 7A). This evidence concerns the gene PLCG2 and diffuse large B-cell lymphoma.